Table 2.

Clinical and molecular characteristics by smoking status in KRAS-mutant NSCLC patients tested for LKB1 IHC (n = 154)

CharacteristicKRAS-mutant NSCLC
SmokersNever-smokers
n (%)n (%)P
Total (n)123 (80)31 (20)
Median age, y (range)64 (41–84)65 (20–84)0.60
Sex
 Female86 (70)23 (74)0.83
 Male37 (30)8 (26)
Smoking history
 Former91 (74)
 Current32 (26)
 Pack-years, median (range)30 (2–120)
Race
 Caucasian114 (93)27 (88)0.08
 Asian0 (0)2 (6)
 Afro-American5 (4)2 (6)
 Hispanic1 (1)0 (0)
 Declined/unknown3 (2)0 (0)
Histology
 Adenocarcinoma109 (89)30 (97)0.92
 Squamous0 (0)0 (0)
 Adenosquamous3 (2)0 (0)
 Large cell3 (2)0 (0)
 NOS8 (7)1 (3)
Stage (AJCC 7th edition)
 I33 (27)8 (26)0.24
 II14 (11)6 (19)
 III10 (8)5 (16)
 IV66 (54)12 (39)
Type of KRAS mutation
 Transversion101 (82)11 (35)<0.001
 Transition22 (18)20 (65)
KRAS mutation
 G12C49 (40)2 (6)<0.001
 G12V22 (18)4 (13)
 G12D19 (15)18 (58)
 G13X5 (4)1 (3)
 Q61X7 (6)0 (0)
 Multiple5 (4)1 (3)
 Others16 (13)5 (16)